Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MYMD |
---|---|---|
09:32 ET | 10383 | 2.45 |
09:34 ET | 1067 | 2.4312 |
09:45 ET | 100 | 2.44 |
09:54 ET | 243 | 2.4 |
10:12 ET | 100 | 2.4 |
10:33 ET | 2427 | 2.44 |
10:44 ET | 1735 | 2.435 |
10:50 ET | 200 | 2.425 |
11:13 ET | 106 | 2.4424 |
11:42 ET | 250 | 2.43 |
11:49 ET | 500 | 2.4292 |
11:54 ET | 100 | 2.4299 |
12:16 ET | 3249 | 2.39 |
12:20 ET | 695 | 2.4 |
12:41 ET | 1516 | 2.38 |
12:50 ET | 500 | 2.37 |
02:04 ET | 233 | 2.39 |
02:09 ET | 111 | 2.3769 |
02:27 ET | 167 | 2.3999 |
02:36 ET | 996 | 2.4 |
02:49 ET | 109 | 2.37 |
02:54 ET | 143 | 2.4 |
03:30 ET | 200 | 2.35 |
03:36 ET | 744 | 2.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mymd Pharmaceuticals Inc | 4.9M | -0.4x | --- |
Biostax Corp | 4.8M | -3.0x | --- |
Artelo Biosciences Inc | 4.7M | -0.5x | --- |
ProtoKinetix Inc | 5.1M | -16.0x | --- |
Tharimmune Inc | 5.1M | 0.0x | --- |
Genprex Inc | 5.2M | -0.1x | --- |
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.30 |
EPS | $-5.53 |
Book Value | $11.17 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.